To the best of our knowledge, this is the first report demonstrating the potential of JNJ-64619178, PRMT5 inhibitor as a radiosensitizer, and FIR-induced NED inhibitor for prostate cancer treatment. This evidence concerns the gene PRMT5 and prostate carcinoma.